octocog alfa (Takeda)

Recombinant antihemophilic factor (Factor VIII) is a purified glycoprotein produced by recombinant DNA technology, used for the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency). It serves as a direct replacement for the missing or deficient endogenous coagulation factor VIII. In the blood, Factor VIII acts as an essential cofactor for activated Factor IX (FIXa); together with calcium and phospholipids, they form the 'tenase' complex, which proteolytically activates Factor X to Factor Xa. This activation is a critical step in the intrinsic pathway of the coagulation cascade, leading to the generation of thrombin and the subsequent formation of a stable fibrin clot. Modern recombinant versions, such as octocog alfa (Advate), are often manufactured using protein-free methods (PFM) to eliminate the risk of pathogen transmission from human or animal-derived additives. The drug is typically administered via intravenous injection.

Brand names

AdvateKogenate FSHelixate FSRecombinateKovaltryNovoeightXynthaNuwiqAfstyla

Other names

recombinant antihemophilic factorrecombinant human coagulation factor VIIIantihemophilic factor (recombinant)moroctocog alfaturoctocog alfasimoctocog alfalonoctocog alfasusoctocog alfa